NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization270.73 mln
Float61.46 mln
Earnings Date11/04/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
7.22
Highly suspicious
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.82
Moderate leverage
Pre-Tax Margin
-62%
Severely loss-making
ROE
-31.28
Deeply negative
Business Description
MacroGenics is a US-based biopharmaceutical company focused on developing antibody-based treatments for cancer. Its pipeline includes several promising therapies, ranging from molecules that help the immune system attack tumors to antibody-drug conjugates that deliver targeted payloads directly to cancer cells, with programs spanning early research through active clinical trials. The company works alongside partners such as Incyte Corporation and Gilead Sciences to advance its treatments. Founded in 2000 and based in Rockville, Maryland, MacroGenics continues to build on its expertise in antibody engineering to address a range of difficult-to-treat cancers.
